DOJ Moves FDA Approved and Medical Marijuana to Schedule III - ArentFox Schiff
DOJ has moved FDA approved and medical marijuana to Schedule III, affecting regulatory compliance for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers involved in the production or distribution of FDA approved and medical marijuana products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action required to ensure compliance with new regulations.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA approved and medical marijuana is now classified as a Schedule III controlled substance, altering compliance requirements.
Who it affects
All pharmaceutical manufacturers involved in the production or distribution of FDA approved and medical marijuana products.
What you must do
Review and update compliance protocols to align with Schedule III regulations, including potential changes to manufacturing practices and distribution.
Deadline
Immediate action required to ensure compliance with new regulations.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- EMA and FDA set common principles for AI in medicine development - ema.europa.eu
- The FDA no longer requires all drugs to be tested on animals before human trials - opb.org
- FDA Selects Seven Companies for Drug Manufacturing Pilot - themedicinemaker.com
- U.S. signals crackdown on compounded weight-loss drugs; Hims shares tumble - CNBC
- US FDA launches program to boost domestic drug manufacturing - reuters.com